Evidence map›Paper›PMID 35838232›Full record

ArticleCombinatorial chemistry & high throughput screening2023

Penehyclidine Hydrochloride Protects Rat Cardiomyocytes from Ischemia- Reperfusion Injury by Platelet-derived Growth Factor-B.

Yan Lu, Congna Zi, Liang Zhang, Boqun Cui, Ling Li, Jun Ma

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yan LuDepartment of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Congna ZiDepartment of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China.
Liang ZhangDepartment of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Boqun CuiDepartment of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Ling LiDepartment of Anesthesiology, Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Jun MaDepartment of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Beijing Anzhen Hospital · CNAffiliated Hospital of Chengde Medical College · CNCapital Medical University · CNHebei North University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS AND

objectiveThe lack of effective treatments for myocardial ischemiareperfusion (MI-R) injury severely restricts the effectiveness of the treatment of ischemic heart disease. In the present research, we aimed to investigate the protective effect and molecular mechanism of penehyclidine hydrochloride (PHC) on MI-R cells.

methodsCell viability was quantified using CCK8. Cell apoptosis was analyzed using flow cytometry. Western blot and Elisa assays were used for the detection of target proteins.

resultsPHC pretreatment attenuated the inhibition of cell viability and decreased the percentage of apoptosis induced by simulated ischemia reperfusion (SIR). Platelet-derived growth factor B (PDGF-B) and its downstream AKT pathway were activated in PHC pretreated cells. After siRNAPDGF- B transfection, cell viability was inhibited and apoptosis was activated in PHC pretreated SIR cells, suggesting that PHC protected cells from SIR. PDGF-B knockdown also increased the levels of CK, LDH, IL-6 and TNF-α in PHC pretreated SIR cells. The effect of AKT inhibitor on H9C2 cells was consistent with that of PDGF-B knockdown.

conclusionPHC pretreatment can protect cardiomyocytes from the decrease of cell activity and the increase of apoptosis caused by reperfusion through up-regulating PDGF-B to activate PI3K pathway. Our study indicates that PHC is a potential drug to protect cells from reperfusion injury and PDGF-B is a potential target for preventing MI-R injury.

Indexed as

Myocytes, CardiacReperfusion InjuryAnimalsApoptosisIschemiaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-sisQuinuclidinesRatsRats, WistarpenehyclidinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-sisQuinuclidinesApoptosiscell viabilityH9C2inflammatory factorsmyocardial ischemia-reperfusion injurypenehyclidine hydrochloride

Identifiers

PMID35838232
PMCPMC10236564
OpenAlexW4285592913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.